These targets include ROS Proto-Oncogene 1 (ROS1), MET Proto-Oncogene (MET) exon 14 skipping mutation, RET Proto-Oncogene (RET), Neurotrophic Receptor Tyrosine Kinase (NTRK), B-Raf Proto-Oncogene (BRAF), and KRAS Proto-Oncogene (KRAS). Both crizotinib and entrectinib, multi-targeted TKIs, are now U.S. Food and Drug Administration (FDA)-approved for treatment of NSCLC patients with ROS1-rearranged mutations (40, 43). This evidence concerns the gene BRAF and non-small cell lung carcinoma.